UnitedHealth Group, a leading US health insurer, faces temporary margin pressure due to high medical costs and regulatory limits on premium increases. The company is seen as undervalued, with a potential 67% upside as it recovers margins through repricing, benefit cuts, and dropping unprofitable plans over the next several years. Management expects earnings growth to return to 13-16% long-term, with headwinds easing by 2026-2027. Despite risks, the stock is considered a strong market opportunity with a wide margin of safety.
The SCHD ETF has returned just under 2% in the past month, outperforming the S&P 500 ETF (SPY) by nearly 1%. Year-to-date, about 30 SCHD holdings have more than doubled the returns of SPY, which has returned 9.8%. Additionally, 31 SCHD holdings are t...
Elevance Health and UnitedHealth Group, two of the largest U.S. health insurers, are set to report their second-quarter earnings this week. Investors and analysts are watching closely to see if these companies have maintained control over rising medi...
